Asia Fresh News

Asia Fresh Stories

Archive for January 18th, 2011

Safety and Efficacy of OrbusNeich’s Genous(TM) Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy

leave a comment »

Results Published in EuroIntervention Indicate Positive Clinical and Safety Outcomes in High-Risk Patients Who Are Not Suitable for Treatment with Drug Eluting Stents (DES)

HONG KONG, Jan. 17, 2011 /PRNewswire-Asia/ — Data from patients who are considered high-risk due to underlying clinical conditions and who cannot be treated with drug eluting stents (DES) and the accompanying requirement of long-term dual antiplatelet therapy (DAPT) showed positive safety and short- and long-term clinical outcomes following treatment with OrbusNeich’s Genous Stent, according to a study published online in EuroIntervention (published-ahead-of-print, August 2010). Known contraindications for DAPT include hypersensitivity or allergy to aspirin, a hemorrhagic risk, or a planned surgery shortly after percutaneous coronary intervention (PCI) that would require cessation of DAPT.

In the study, the major adverse cardiac events (MACE) free survival rate in patients treated with the Genous Stent was 80.6% after one year. Between year one and year two, no additional MACE were observed. In patients who underwent surgical treatment shortly after PCI, no perioperative MACE or thrombotic events occurred. Despite a very short period of DAPT use of 15 to 30 days, there were no cases of sub-acute, late or very late stent thrombosis in treated patients. The cumulative incidence of cardiac death was 1.6%, which is low considering the high risk patient population.

“The Genous Stent is an important and extremely attractive option for interventional cardiologists to safely manage high-risk patients who are contraindicated for prolonged DAPT and, therefore, should not receive a DES,” said Paolo Scacciatella, M.D., Ph.D., of the Molinette Hospital Turin, Italy, and principal investigator of the study. “This is the first study that demonstrates the feasibility and efficacy of the Genous Stent in this particular segment of patients who are challenging to treat.”

Emanuele Meliga, M.D., Ph.D., FESC, of Ordine Mauriziano Hospital in Turin, Italy, and corresponding author of the publication added, “We have observed that the Genous Stent, which accelerates the natural healing process, enables a shorter post-procedural period of DAPT without increasing the risk of late or very late stent thrombosis and without causing dangerous delays for patients who require noncardiac surgery shortly after PCI.”

The single-center study investigated 61 high-risk patients with a clear contraindication to prolonged DAPT. A high-risk condition was defined as meeting at least two of the following criteria: diabetes, acute coronary syndrome, heart failure, proximal vessel disease, multivessel disease, B2/C type lesions, bifurcating lesions and long lesions. The study’s primary outcome measures were the occurrences of death, MI, target vessel revascularization (TVR), target lesion revascularization (TLR) and MACE, defined as a non-hierarchical composite of all cause death, nonfatal MI or repeat revascularization.

“This study adds to the growing body of knowledge published in peer-reviewed biomedical publications that supports the use of Genous for the treatment of challenging coronary indications,” said Stephen M. Rowland, Ph.D., vice president of research and development at OrbusNeich. “We see in this case that high-risk patients with confounding co-morbidities precluding the use of DES still have an option that is safe and effective in the long-term.”

About Genous

Genous is OrbusNeich’s patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in companysponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world’s first pro-healing stent, the Genous Stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent, Scoreflex(TM), Sapphire(TM) and Sapphire NC. Development stage products include the Combo(TM) Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit .


Written by asiafreshnews

January 18, 2011 at 3:12 pm

Posted in Uncategorized

Tagged with

TalariaX Achieves RSA Secured(R)Partner Program Certification to Deliver On-Demand Authentication services over SMS

leave a comment »

2011-01-18 12:00 


TalariaX’s sendQuick® is Asia’s first appliance-based SMS gateway for enterprises to receive this certification

SINGAPORE, Jan. 18, 2011 /PRNewswire-Asia/ — TalariaX Pte Ltd., a Singapore incorporated company delivering innovative wireless applications, announced that it has joined the RSA Secured Partner Program and certified interoperability between sendQuick and RSA® Authentication Manager from RSA, the Security Division of EMC. This allows administrators using RSA Authentication Manager to use TalariaX sendQuick®for delivery of token codes via text messages for on-demand authentications.

Mr. Wong Jeat Shyan, CEO, TalariaX said, “We are very excited to join the RSA Secured Partner Program and to achieve interoperability certification. The TalariaX sendQuick® appliance-based text messaging gateway will offer RSA customers direct delivery of highly secured messaging. sendQuick® helps increase message reliability and dependency for enterprise communication by offering local delivery of all SMS.”

Since the first roll out in 2002, sendQuick® SMS gateway is used by more than 950 enterprise companies worldwide in applications such as IT Alerts and Notifications, 2-Factor Authentication, SMS job dispatch, Customer Relationship Management, SMS marketing, and many more.

TalariaX sendQuick® is a plug-and-play appliance which has HTTP plug-in features including,

– Out-of-the box (seamless) integration with RSA AM7.1 SP4
– Support for HTTP and HTTPs, for secure transactions
– Support for multiple SMS message formats (Text, Flash SMS and Message Overwrite)
– Filter rules for mobile number matching and pre-processing
– Simple web-based configuration
– Zero maintenance appliance
– Messages are logged (Send, Queued, Failed) for recording and archiving

TalariaX sendQuick® is designed to benefit RSA customers with:

– Local delivery for all SMS, helping to increase message reliability and dependency (no 3rd
party involvement)
– Local delivery helps ensure lowest SMS delivery cost
– High security and reliability as SMS transmission is within the local network (Intranet)
– Use SMS OTP for primary authentication, backup 2FA or 2FA for on-demand remote access for
– Lower SMS OTP implementation cost  as it is a plug-and-play appliance

“TalariaX sendQuick® offers a contained system that gives enterprises visibility and control of SMS delivery to only those end users provisioned with on-demand authentication credentials. It’s an additive solution to RSA Authentication Manager for those enterprises seeking flexible on-demand authentication at lower costs,” said Sam Curry, CTO, Marketing for RSA, the Security Division of EMC.

sendQuick® is available worldwide through TalariaX’s global network of distributors and resellers. Further details of resellers in different regions:
About the RSA Secured Partner Program

The RSA Secured Partner Program is one of the largest and longest-running technology alliance programs of its type, bringing over 1,000 complementary solutions across more than 300 organizations together. RSA SecurID®, RSA® Access Manager, RSA® Adaptive Authentication, RSA® Digital Certificate Solutions, RSA Hybrid Authenticators, the RSA enVision® Platform,  RSA® Federated Identity Manager and RSA® Key Manager Suite certification programs bring added assurance to customers that their solutions are certified as interoperable to help them achieve faster time to deployment and lower overall cost of ownership. The RSA Secured Partner Program reflects RSA’s commitment to driving inventive collaboration across the industry and support standards-based interoperability with its information-centric security solutions to help protect information, identities and infrastructures. Please visit

About TalariaX Pte Ltd

TalariaX Pte Ltd is a Singapore incorporated company focusing on mobile application development specifically on SMS, MMS and 3G technologies.  TalariaX sendQuick is the industry’s first appliance based SMS gateway, for enterprise messaging.  Launched in 2002, sendQuick is used by more than 950 companies worldwide in all industries including banking, finance, insurance, manufacturing, retail, government, healthcare and many more.  Started with a single model, today sendQuick has 6 different models for different solutions like IT notifications, marketing, SMS OTP, SMS transaction and many others.  sendQuick support the key mobile technologies including GSM and CDMA. Website:

RSA, SecurID, envision and Secured are either registered trademarks or trademarks of EMC Corporation in the United States and/or other countries.  All other products and/or services referenced are trademarks of their respective companies.

Media contacts:
Rice Communications on behalf of TalariaX
Suzanne Yap
Contact: +65-8522-3221

Debbie Ho
Contact: +65-8333-1160


SOURCE TalariaX Pte Ltd.


Written by asiafreshnews

January 18, 2011 at 2:38 pm

Posted in Technology